The year's new drugs & biologics 2018: Part II - News that shaped the industry in 2018

• Graul, A.I. ^[1] ; Dulsat, C. ^[1] ; Pina, P. ^[1] ; Cruces, E. ^[1] ; Tracy, M. ^[1]
  1. [1] Clarivate Analytics, Barcelona, Spain
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 2, 2019, págs. 131-160
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • This eagle's-eye overview of the drug industry in 2018 provides insight into some of last year's top stories, including a large and still growing outbreak of Ebola in the Democratic Republic of the Congo, as well as the potential uses (and abuses) of CRISPR technology. As in previous years, we also review orphan drug development, new regulatory agency-supported programs such as Priority Medicines Scheme (PRIME) and Sakigake, pipeline attrition, and pharma/biotech mergers and acquisitions of note. Finally, we take a glimpse into the crystal ball to anticipate the new drugs that will be approved in 2019.